FIELD: pharmacology.
SUBSTANCE: group of inventions concerns a liquid aqueous pharmaceutical preparation containing a human anti-TNFα antibody, namely: adalimumab at a concentration of 100 mg/ml, 1 mg/ml of polysorbate-80, 42 mg/ml of mannitol and water. Also, methods for treatment of diseases associated with harmful TNFα activity, by drug administration to the patient are proposed.
EFFECT: increased bioavailability with subcutaneous administration to the subject, reduction of pain associated with drug injection in the subject.
21 cl, 26 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE COMPOSITIONS WITH HIGH CONCENTRATIONS OF PROTEINS OF HUMAN ANTIBODIES AGAINST TNF-ALPHA | 2010 |
|
RU2560701C2 |
| ANTIBODY PURIFICATION | 2007 |
|
RU2466740C2 |
| METHODS AND COMPOSITIONS FOR DIAGNOSTICS OF ANKYLOSING SPONDYLITIS WITH APPLICATION OF BIO-MARKERS | 2006 |
|
RU2438704C2 |
| AUTOMATIC INJECTION DEVICE | 2007 |
|
RU2438721C2 |
| AUTOMATIC INJECTOR | 2007 |
|
RU2575906C2 |
| METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLARTHRITIS BY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | 2016 |
|
RU2728710C2 |
| TREATMENT OF PURULENT HIDRADENITIS | 2018 |
|
RU2772202C2 |
| USE OF IL-17 ANTAGONISTS FOR INHIBITION OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS | 2015 |
|
RU2697383C2 |
| FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
| SEPARATION AND PURIFICATION OF ANTIBODIES WITH APPLICATION OF PROTEIN A-BASED AFFINITY CHROMATOGRAPHY | 2009 |
|
RU2520838C2 |
